Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
232.8 USD | -1.16% | -2.54% | +0.51% |
04-24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
04-22 | RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 32.26 and 26.99 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.54 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.51% | 42.86B | B | ||
+12.08% | 42.74B | B- | ||
+44.30% | 41.36B | A | ||
-6.20% | 27.68B | C | ||
+5.78% | 25.15B | B- | ||
-23.61% | 18.63B | B | ||
+28.27% | 12.37B | C+ | ||
-3.41% | 11.92B | C+ | ||
+7.04% | 11.21B | B+ | ||
-17.19% | 10.14B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IQV Stock
- Ratings Iqvia Holdings Inc.